Kazia Therapeutics Appoints Scientific Architect Dr. Sudha Rao as CSO to Lead Oncology Platform
Summary
Kazia Therapeutics has appointed Dr. Sudha Rao as its new Chief Scientific Officer. Dr. Rao is a highly accomplished translational scientist and is noted as the scientific originator of the epigenetic framework underlying paxalisib and a pioneer in next-generation therapeutic platforms, including the SETDB1-targeted chromatin modulation program. This appointment follows Kazia's recent licensing of a novel SETDB1-targeted epigenetic platform from QIMR, where Dr. Rao holds a professorial appointment. Her expertise is expected to significantly strengthen the company's R&D capabilities, advance its pipeline, and support an integrated oncology platform strategy, which is a material development for this clinical-stage biotech.
At the time of this announcement, KZIA was trading at $10.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $107.2M. The 52-week trading range was $2.86 to $17.40. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.